| Literature DB >> 28101516 |
Paweł Maga1, Brandon Michael Henry2, Elizabeth K Kmiotek2, Iwona Gregorczyk-Maga3, Paweł Kaczmarczyk1, Krzysztof A Tomaszewski2, Rafał Niżankowski1.
Abstract
The aim of this study was to measure the sensitivity and specificity of transcutaneous oxygen tension and postocclusive hyperemia testing using laser Doppler flowmetry in patients with primary Raynaud's phenomenon. One hundred patients and one hundred controls were included in the study. Baseline microvascular blood flow and then time to peak flow following occlusion were measured using laser Doppler flowmetry. Afterwards, the transcutaneous oxygen tension was recorded. The sensitivities of baseline microvascular blood flow, postocclusive time to peak flow, and transcutaneous oxygen tension were 79%, 79%, and 77%, respectively. The postocclusive time peak flow had a superior specificity of 90% and area under the curve of 0.92 as compared to 66% and 0.80 for baseline microvascular flow and 64% and 0.76 for transcutaneous oxygen tension. Time to postocclusive peak blood flow measured by laser Doppler flowmetry is a highly accurate test for differentiating patients with primary Raynaud's phenomenon from healthy controls.Entities:
Mesh:
Year: 2016 PMID: 28101516 PMCID: PMC5215461 DOI: 10.1155/2016/9645705
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Position of the probes and measuring equipment on the hand: (a) TcPO2 probe, (b) pressure cuff, (c) thermometer, and (d) LDF probe and probe holder.
Figure 2Difference in values obtained for bMBF, tpMBF, and TcPO2 between controls and patients with primary RP. bMBF: baseline microvascular blood flow; tpMBF: postocclusive time to peak microvascular blood flow; TcPO2: transcutaneous oxygen tension.
Sensitivity and specificity of the diagnostic tests.
| Cut-off value | Sensitivity | 95% CI | Specificity | 95% CI | PPV | 95% CI | NPV | 95% CI | |
|---|---|---|---|---|---|---|---|---|---|
| bMBF | ≤19.3 PU | 79% | 69.7–86.5 | 66% | 55.8–75.2 | 69.9% | 60.6–78.2 | 75.9% | 65.5–84.4 |
| TcPO2 | ≤62.6 mmHg | 77% | 67.5–84.8 | 64% | 53.8–73.4 | 68.1% | 58.8–76.6 | 73.6% | 63.0–82.5 |
| tpMBF | >7.2 seconds | 79% | 69.7–86.5 | 90% | 82.4–95.1 | 88.8% | 80.3–94.5 | 81.1% | 72.6–87.9 |
PPV: positive predictive value; NPV: negative predictive value; 95% CI: 95% confidence interval.
Figure 3ROC curves of the predictive power of basal microvascular blood flow, LDF measures of time to max blood flow following vascular occlusion, and TcPO2 on the presence or absence of Raynaud's syndrome. bMBF: baseline microvascular blood flow; tpMBF: postocclusive time to peak microvascular blood flow; TcPO2: transcutaneous oxygen tension.
Area under the curve (AUC) for the three diagnostic techniques examined.
| AUC | SE | 95% CI |
| |
|---|---|---|---|---|
| bMBF | 0.8029 | 0.0301 | 0.7439–0.8619 | <0.0001 |
| tpMBF | 0.9212 | 0.0190 | 0.8840–0.9583 | <0.0001 |
| TcPO2 | 0.7589 | 0.0334 | 0.6935–0.8213 | <0.0001 |
SE: standard error; CI: confidence interval.
(a) Patient's diagnosed with Raynaud's syndrome
|
| Minimum | Maximum | Mean | Standard error | Standard deviation | |
|---|---|---|---|---|---|---|
| bMBF (PU) | 100 | 4.30 | 33.2 | 15.2 | 0.645 | 6.45 |
| tpMBF (seconds) | 100 | 3.00 | 65.0 | 16.4 | 1.070 | 10.7 |
| TcPO2 (mmHg) | 100 | 34.2 | 84.2 | 56.2 | 0.972 | 9.73 |
(b) Controls
|
| Minimum | Maximum | Mean | Standard error | Standard deviation | |
|---|---|---|---|---|---|---|
| bMBF (PU) | 100 | 10.20 | 46.10 | 24.7 | 0.936 | 9.36 |
| tpBF (seconds) | 100 | 1.60 | 46.10 | 4.87 | 0.175 | 1.75 |
| TcPO2 (mmHg) | 100 | 45.90 | 91.10 | 66.7 | 1.080 | 10.8 |